Randomized, Multicenter, Open-label, Active-Controlled, Phase 2 Study of LY2510924 and Sunitinib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 26 Dec 2016
At a glance
- Drugs LY 2510924 (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 21 Dec 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2017.
- 18 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
- 02 Jun 2015 Primary endpoint (Progression free survival) has not been met, according to results presented at ASCO 2015.